EMSP Annual Congress 2012

Barcelona | 19th - 20th May





What you should know about MS and EMSP:

Multiple sclerosis (MS) is a complex, chronic, disabling disease, disrupting the transmission of signals in the brain. The average age of diagnosis is 20-40, a period when individuals are highly engaged in establishing their careers, raising their families and enjoying lifestyles. MS affects twice as many women as men. There are currently approximately 600,000 people diagnosed with MS in Europe each year. So far, no cure has been found.

The European Multiple Sclerosis Platform (EMSP) is the umbrella organisation for 38 MS societies from 34 European countries. EMSP represents their interests at the European level and works to achieve its goals of high quality equitable treatment and support for people with MS.

Its activities derive from a a mission comprising five main objectives:

- Encourage MS research through recognised organisations
- Exchange and disseminate information relating to MS
- Promote collaborative programmes among national MS societies in Europe
- Facilitate interaction between institutions of the European Union, the Council of Europe and other organisations
- Propose new measures to advance the rights of people with MS and ensure their participation in society

Gee Ma Pro Pro Ca Pro Ca Pro Th Joi Er Lui A Ke

pening Address to MS Conference	04
ohn C. Golding Norway, EMSP President	
pening Session	05
osep Lluís Cleries i Gonzàles, Minister of Social Welfare and Family, Generalitat of Catalunya Spain	
merging Therapies for Multiple Sclerosis	06
rof. Alan J. Thompson, University College London UK	
iender Differences in Multiple Sclerosis	10
lar Tintoré, PhD, MS Centre of Catalonia (Cemcat) Spain	
rogress in Remyelination Research	14
rof. Catherine Lubetzki, Hôpital Pitié-Salpêtrière France	
cannabis in the Management of MS symptoms	18
rof. Patrick Vermersch, University of Lille Nord de France France	
hreats to Adequate MS Treatment in Portugal	22
orge Da Silva, MS Society of Portugal Portugal	
mpowerment Case for Poland	24
uiza Wieczyńska, MS Society of Poland (PSTR) Poland	
"Starting Point" for Living with MS ent Andersson, MS Society of Sweden Sweden	26
lational Political Developments in Health and Social Care since 2003 in Serbia	27
ena Dujmović Bašuroski, MD, PhD, Ass. Prof., University of Belgrade Serbia	21
ecent Developments in Patient Involvement in the EMA	30
se Murphy, co-chair at PCWP, patient representative at EURORDIS and hristoph Thalheim, EMSP representative at PCWP	
/ORKSHOPS	
Workshop A EUReMS: Background, Structure and Expected Outcomes	31
Dr. Jaume Sastre-Garriga, CEM-Cat, Barcelona and Dr. Tsveta Schyns-Liharska, EMSP	
Workshop B Certified Online Training for MS Nurses in Europe	32
Anne Winslow, EMSP Vice-President	
Workshop C MS Barometer and UNDER PRESSURE: Living with MS in Europe	34
Elisabeth Kasilingam, Marilyn Smith, Walter Astrada, Fernando Moleres, Lurdes Basolí, Maximiliano Braun, Carlos Spottorno and Jesús Mora López-Almodovar (PwMS)	
MSP Youth Congress 2011 Report	36

Table of Contents

Opening Address to MS Conference



Volem agrair la presència avui amb nosaltres del Ecellentissim senyor Conseller de Benestar Social i Familia de La Generalitat de Catalunva.

For those of you that do not speak Catalan I have just said "First of all I would like to welcome the minister for Social Welfare and Family in The Generalitat of Catalonia": Mr. Josep Lluis Cleris I Gonzáles.

I would also like to welcome all the speakers that will be addressing us during these three days and last but not least all the participants and guests taking part in this conference. That is to say CEOs and key staff volunteers of MS societies in Europe, representatives of MSIF, people with MS and their

caregivers, Young persons with MS, neurologists, In our workshops representatives of RIMS. ECTRIMS. MS nurses. industry representatives and anyone else attending and interested in the issue of MS. It is my hope that those of you that are here for the first time took part in the Tour of Barcelona yesterday evening and savoured some of the stunning spectacles on offer in this beautiful city.

We have had a meeting of medical experts and the Annual Council meeting yesterday and we are now ready to move on by holding the Annual Conference and Youth Congress.

The EMSP is a platfrom for exchange of MS related information and examples of good practice. There are various channels for this task - our traditional Spring Conference is one of the most effective and important ones.

I would like to say a few words as to what you can expect Catalonia. to be addressed and discussed today and tomorrow.

As always in our Spring Conferences: A leading expert will present an update on new MS treatments in the pipeline (Prof. Alan Thompson).

We'll learn about:

- The impact of female hormones on MS
- About the progress in re-myelination research
- About cannabis in management of MS symptoms and

- We will try to bring you closer to current EMSP ٠ projects and to a promising pilot project in Switzerland on MS and employment
- In parallel, the YPwMS will have their own discussions about sexuality and pregnancy.
- We'll hear about national political developments in healthcare and social care since 2003, the year of the EU Parliament's Resolution on MS
- And finally, we'll try to inspire you by some examples of good practice in patient empowerment, taken both from national and from European level.

It is my sincere wish that you will find the programme interesting and rewarding and that it also allows you to socialise and renew old friendships and also make new friends and contacts at the same time.

I will now like to give the floor to Councillor Josep Lluís Cleries i Gonzáles from The Generalitat of

Opening Session



across Europe.

poor economic standing, and social isolation.

More recently, the government has put emphasis on defining disability and dependency, with the

positive action - within society.

employment, social activity and independent living. ways: "take a dip" or "get engaged". It also means looking at disease from a societal perspective, not just from the angle of health and It is my heartfelt wish that this message will spread healthcare costs.

To open this 2012 Annual Congress, I want first to Through the Ministry of Health and the Ministry congratulate the EMSP on its sterling work in the of Social Welfare and Family, the Government of area of MS, which I believe has brought benefits Catalunya is committed to early, effective and multi- evolves. to all the national MS Societies represented in this disciplinary treatment for all people with MS. We room and to the 600,000 people living with MS aim to be patient-centred and believe that people Given the current economic crisis in Spain, we are with MS understand best what their needs are - in a time when it is particularly difficult to move and that we should listen to them and learn from forward in advancing in these areas. But we see an As you all know, Spain as a whole and its them how to best meet those needs. Then we have event like this as an occasion to learn from others individual regions have had a long, hard struggle a responsibility to coordinate our support so that and, hopefully, to advance more quickly and at to achieve a welfare state. For many decades, the these people who already have so many additional lower cost based on their experiences. With this in rights of people with disabilities received very little burdens because of MS do not have to waste their mind, I wish you a very successful and engaging attention; they often lived in states of poor health, time and energy trying to make their way through Congress. a labyrinth of bureaucracy. It is our job to provide comprehensive services in an efficient manner.

aim of highlighting the right for each person to Governments also need to take measures to break be as able and independent as possible at any down the stigma that persists. In this regard, we given moment in his or her life. Our intent is to often look for guidance from the MS societies who recognise appropriately the value of each person's are close to the community and know the challenges. capacity, and to be sure that each feels she or he One activity I believe to be highly effective, which is is a protagonist – that is someone who advances organised each year by the *Federación Española* para la Lucha contra la Esclerosis Múltiple (FELEM) is known by the slogan MULLA'T. People To achieve this, governments have the responsibility who enjoy swimming – as do many people who to create an accessible society; this implies have MS - seek sponsors who will contribute a philosophies and practical action in areas such sum of money for each kilometre they swim. The as universal access and eliminating barriers to slogan of the campaign can be translated as in two

> throughout the able-bodied community, and that many more of people will engage in the effort to ensure that all people with MS receive dignified care throughout their lives, particularly as their condition



UCL

The unmet need is massive

Disease modification			
MRI, relapse reduction, delayed onset of CDMS, delayed disease progression, disease activity free, delayed onset of SPMS, prevention of SPMS			
Anti-inflammatory strategies	Neuroprotective Neurorestorativ strategies strategies		
Symptomatic therapies			
Cognition	Fatigue	Spasticity	
Bladder/Bowel	Mobility	Mood	
MS prevention			
Vitamin D	Smoking	EBV	
Vitamin D	Smoking	EBV	

Emerging Therapies and Multiple Sclerosis

for MS (Interferon-B) was approved by the US the blood-brain barrier; and protecting the CNS Food and Drug Administration, we can see from demyelination or restoring the damage done encouraging milestones in the development of to it. In the case of relapsing-remitting MS (RRmore therapeutic options. Just five years later, MS), one of the key areas is that of **monoclonal** four agents were available that reduced relapse **antibodies**, which target specific molecules. rates. Between 2004 and 2006. a second-line agent was licensed for more aggressive MS, The story of **Natalizumab** is well known: the withdrawn because of serious side effects and therapy aims to seal the blood-brain barrier, a new era of therapy, with the release of the first central nervous system (CNS) and attack tissue. oral agent.

terms of ensuring access to disease-modifying risk of disability progression. But controversy drugs world-wide and in developing strategies to arose from evidence that the treatment suppress inflammation and to protect and repair increased the risk of developing progressive the central nervous system. There is also great multifocal leukoencephalopathy (PML). Further need in symptomatic treatment and in prevention investigation saw the risk for PML increase from of MS.

The pipeline of therapies under development include: reflects that research in MS therapies continues in three areas: regulating the immune system;

Twenty years after the first effective medication finding ways to keep leukocytes from crossing

subsequently reintroduced. In 2010, we entered making it impossible for leukocytes to enter the In clinical trials against placebo over two years, Natalizumab showed an 81% reduction in the Yet the unmet needs are very challenging in annual relapse rate and a 64% reduction in the 1:1000 to 2.3:1000, but also provided better understanding of the risk factors involved, which

> the time period over which a PwMS is treated with • Natalizumab:



- previous immune-suppression therapies; and
- activation of the virus.

Importantly, methods have been developed to screen for JCV antibodies, making it possible to more informed decisions about risks, monitor the effects of treatment and make appropriate decisions as needed.

New monoclonal antibody therapies now either available or in Phase III clinical trials include Alemtuzumab, Ocrelizumab and Daclizumab¹ all of which focus primarily on reducing the risk of attacks in RR-MS.

With patient quality of life in mind, much effort has gone into developing oral therapies as an alternative to those delivered by injection or infusion. At present, four agents are either available or in the process of becoming so; Teriflunomide.

The greatest interest is on Fingolimod (marketed • the presence of virus (JCV) antibodies and the as Gilenya), which works by "sweeping up" the lymphocytes that attack the CNS. Two large clinical trials have shown positive results. In the TRANFORMS study, Fingolimod was tested identify PwMS who are most at risk for PML. As against interferon b-1a; similar results were treating neurologists, we can help patients make seen in the FREEDOMS trial, which compared Fingolimod with placebo. As a result of these trials, Fingolimod was approved for two groups:

- Patients with high disease activity despite treatment with a beta-interferon.
- Patients with ≥ 2 relapses in one year, and ≥ 1 Gdenhancing lesion or a significant increase in T2 lesion load.

The studies revealed the need to monitor three areas of potential adverse effects: cardiovascular effects, a higher degree of respiratory infections and the development of malignancies (though no specific association has been verified).

Fumaric acid (Fumarate or BG00012) appears Fingolimod, Fumaric Acid, Laquinimod and to dampen inflammation while also protecting against the neuronal death and damage to myelin two years, providing statistically significant improvements for (78 percent ve 38 percent of her years, and 000



in two Phase III trials, one against placebo and depletion and autoimmune thyroid dysfunction one against glatiramer acetate. **Teriflunomide** (23%). is a potent oral immuno-modulator that regulates T-cell function while preserving vital salvage **Ocrelizumab** targets CD20-positive B lymphopathways. A placebo-controlled Phase III trial cytes. At two dose levels (150 mg and 300 mg), by 31% for both doses. The higher dose also in reduced disability progression (57% and 43%). significantly reduced (by 30%) time to disability progression. The drug was well tolerated, had Several of these studies reflect an important the USA.

rate. However, its impact on slowing disability the *added value* of the new therapy. was less significant and the therapy is known to

in the CNS. The therapy has shown positive results have adverse effects including prolonged T-cell

(TEMSO) with two dose groups showed that the SELECT trial showed substantial reductions Teriflunomide reduced the annual relapse rate in relapse rates (54% and 50%, respectively) and

a favorable safety profile and is now licensed in development in how clinical trials for MS are carried out. Previously, all clinical trials involved therapy or no therapy (placebo), which placed half **Alemtuzumab** (Lemtrada) targets CD52 of the trial population at greater risk for relapses receptors on lymphocytes and monocytes. It has and progression of MS. Increasingly, trials include been shown to be effective in early MS, delivering three groups: those on the trial therapy, those better results in terms of relapse reduction taking placebo and those continuing their current than interferon beta-1a. Some 78% of patients therapy. This makes it possible to measure receiving Alemtuzumab remained relapse-free the effect of the trial therapy not only against for two years (against 59% for interferon beta- no therapy, but also against therapies already 1a); this reflects a 55% reduction in relapse proven. The approach facilitates an evaluation of

UCL

Pathological Differences between RRMS and Progressive MS (SPMS, PPMS) SPMS / PPMS RRMS RPMS

Compartmentalized

inflammation in the CNS

Diffuse inflammation and

axonal injury in NAWM

Extensive cortical

demvelination

existing white matter lesions

Slow expansion of pre-

- New waves of inflammation entering the CNS from circulation
- Focal demvelinating lesions with variable axonal injury and blood brain barrier injury mainly in the white matter

Kutzelnigg et al 2005, Hochmeister et al 2006, Frischer et al 2009



Progressive MS (SP-MS), which shows have notably in Italy and by ECTRIMS. The Study unsuccessful.

which may provide an indication of neuroprotec- and efficacy of MSCT. tion are being incorporated.

mesenchymal stem cell therapy on MS CNS damage. patients with previous optic neuritis showed some benefits in visual acuity, latency of evoked The urgent need for therapies for progressive potential and in the area of the optic nerve. MS has prompted the establishment of the The research community recognises the need International Progressive MS Collaborative. A for a more strategic approach to stem cell Consensus paper entitled "Progressive Multiple research, and has established the International Sclerosis: Setting a Research Agenda" has been

for RR-MS. However attempts to find an Study Group, which is supported by the MS five priority areas, for which working groups have effective treatment for people with Secondary International Federation a number of MS charities been convened: been less positive. To date, attempts to apply Group has produced a Consensus paper on • the above drugs to this stage of MS have been the utilisation of MSCs for the treatment of MS (published in *Mult. Scler*. 2010) and on guidelines for Phase I/II clinical trials of MSCT in MS. The In the case of SP-MS, efficacy of the therapy is MESEMS trial, now underway, has a robust assessed by indicators designed to monitor the sample size (~160 subjects) and 10 international development of lesions and Gd+ indicating in- centres participating for a two-year period. It is flammation. Increasingly, measures of atrophy expected to provide valuable data on the safety

Important research is also examining neuroplas-In relation to repair, a very small trial (only ticity - i.e. the ability of the CNS to repair itself 10 patients) that examined the effects of or to find new ways to perform functions despite

Overall, these advances show promising results Mesenchymal Stem Cell Transplantation (IMSCT) published in October's MSJ. The paper identifies

- Experimental models for improved preclinical evaluation of novel therapies.
- Targets/pathways identification and validation/ repurposing of existing therapeutic agents.
- Proof-of-concept clinical trial strategies.
- Clinical outcome measures and trial design.
- Symptom management and rehabilitation strategies.

Looking forward, there are many potential options for progressive MS. But improving accessibility for people with MS and facilitating decision-making are challenges that require upto-date information. Research must focus on progression and on management of side-effects, while also keeping symptomatic management and rehabilitation firmly in the frame.



Gender Differences in Multiple Sclerosis

The predominance of MS in women over men This immune suppression can have a protective - a ratio of approximately 2:1 - is seen also in effect for women with MS (Voskuhl and Gold, other auto-immune diseases. This suggests a Nat. Rev. Neurol., 2012). relation between female reproductive hormones and autoimmunity. This gender link is further The hormonal changes that accompany birth of a evidenced in the fact that in pre-adolescent MS child are often seen to have the opposite effect: the ratio tends to be 1:1 and in statistics showing as levels of Th1 increase and Th2 fall down again, that women in the relapsing-remitting stage tend the risk of a post-natal relapse rises. to have a "more active" form of MS (characterised by more relapses). Although the causes are less These findings are important for women with MS: clear, men appear more likely to advance to the they demonstrate that past beliefs ("pregnancy secondary progressive stage or to be diagnosed may be dangerous for the baby", "a woman with with primary progressive MS.

after pregnancy further confirm this hormonal link. not based on evidence. They also help to answer During pregnancy, Th1 cytokine levels decrease questions that all women with MS ask when while Th2 cytokines increase. With half of the raw considering whether to have a family. material of a foetus coming from the father, the mother's body recognises the growing child as a *Will I have a normal baby?* "foreign invader". To support its development, the **YES.** There is no evidence of MS having negative mother's body naturally suppresses the immune system mechanisms that might otherwise reject the invasion.

MS cannot cope with a mother's duties", "your MS will worsen", "your disease can be passed Studies of women with MS before, during and on to the baby") about pregnancy and MS were

effects (such as malformations or infant death) on the health of offspring (Mueller et al., Am J Obstet Gynecol, 2002), nor are any changes noted for

But the fact remains – across the general population - that approximately 35% of pregnancies are What if I get pregnant while I am on DMD treatunplanned. Thus in certain cases, the foetus could ment? be exposed to the MS therapy during its earliest Most neurologists will advise women with MS to plan stages of development. A first study showed a their pregnancies according to their own wishes, but small increased risk of spontaneous abortion, but taking into account the severity of their disease. All no increase in the risk of congenital abnormalities will recommend stopping treatment before trying to (Boskovic et al., Neurology, 2005); however, other conceive. For DMDs, the treatment should be stopped studies have suggested that the rate of pregnancy approximately one month prior; for Natalizumab and losses for women exposed to interferon beta matches

Patient characteristic	MS incidence (onset)	MS activity (relapse)	MS progression (disability)
Sex	Women more than men	Women more than men	Possibly men more than women*
Late pregnancy (third trimester)	Decrease	Decrease	None
Postpartum	Increase	Increase	None
Parity [‡]	No change (or possibly decreased) with increasing parity	Unknown	No change (or possibly decreased) with increasing parity

*Available evidence does not clearly demonstrate a sex-related difference with regard to disability or progression of disease, *No substantive evidence is available for the effects of parity. Abbreviation: MS, multiple sclerosis.

Sex-related factors in multiple sclerosis susceptibility and progression

Rhonda R. Voskuhl and Stefan M. Gold


is exposed to interferon B in the early stages of development (Boskovic et al., Neurology, 2005).

Will my child have MS?

The risk is slightly increased. In the general population, the incidence of MS is about 0.2%. In cases where the mother or father is affected, the incidence rises to 3% to 5%. For dizygotic (fraternal) twins, the risk is guite low 3% to 5%; for monozygotic (identical) twins, the risk increases substantially to 20% to 26%.

age of walking or talking, or other developmental Fingolimod, it is recommended to discontinue three stages expected in the first year (Patti et al., *J Neurol*, months in advance. The European Medicines Agency 2008). There is no increased risk of low birth weight has four rankings for the risk level of all drugs during (Dahl et al., *Neurology*, 2005), except if the foetus pregnancy; the main MS therapies are shown below:

- Category A: No risk for the foetus.
- Category B: No risk for the foetus observed in animal studies. No controlled studies exist in pregnant women (glatiramer acetate).
- Category C: Animal studies have shown abnormalities in foetus. No controlled studies exist in pregnant women (interferons, Mitoxantrone and Natalizumab).
- Category D: Evidence of teratogenicity and abortions in studies or data during post-marketing.



that of the general population (Sandberg- Will MS cause complications during Wollheim, *Neurology*, 2005). In another study of *pregnancy?* 88 Spanish women, covering both planned and **NO.** There is no evidence that MS increases unplanned pregnancies and reflecting exposure complications during pregnancy in relation to the or non-exposure to DMDs, 75% of pregnancies population at large (Mueller et al., Am J Obstet advanced to full term while 25% were lost (V. De Gynecol, 2002). la Heras, et al., Multiple Sclerosis, 2007). For full-term pregnancies, no malformations or neo- Will I have more relapses during pregnancy? natal complications were reported (Fragoso et Are relapses more severe during pregnancy? al., CNS Drugs, 2010) and the rate of Cesarean The PRIMS study group showed that relapse births matched the general population (Amato et rates declined during pregnancy against the year al., *Neurol*, 2010).

connected with the use of assisted reproduction This appears to be related to lower levels of Th1 techniques, but the findings need to be further and increased levels of Th2. If a relapse occurs investigated and confirmed (Hellwig et al., during pregnancy, physicians are better prepared European Neurology, 2009). Similar findings were to treat, selecting the appropriate therapy true for exposure to Gatilramer acetate (Salminen (typically with methyl prednisolone) in relation to et al., J Neurol, 2010) and to Natalizumab (Hellwig the severity of the attack. et al., MS Journal, 2011), although the data for Natalizumab exposure are very preliminary.

prior to pregnancy; during the third trimester, the rate fell by as much as 70% (Confraveux et al., N One study shows some risk of increased relapse Engl J Med, 1998; Vukusic et al., Brain, 2004).



Will I develop new symptoms during pregnancy?

POSSIBLY. Some women experience an aggravation existing symptoms or notice new symptoms, particularly in the areas of urinary problems, fatigue, sensory symptoms and gait abnormalities.

Will MS cause complications during delivery?

NO. There is no evidence of increased complications born? during delivery (Mia van der Kop et al., Ann Neurol, 2011; Mueller et al., *Am J Obstet Gynecol*, 2002).

Can I have an epidural during delivery?

YES. Available data do not show any increased risk of relapse in response to epidural (Vukusic et al., Brain, 2004).

Can I breastfeed?

YES. There is no evidence that breastfeeding (Vukusic et al., Brain, 2004). increases the rate of relapse or disability (The PRIMS study group, N Engl J Med, 1998). One If an attack occurs post-partum or during breastsmall study suggested that breastfeeding may have a protective role against relapses (Langer-Gould et al., Arch Neur, 2009), but this was not confirmed

relapse rate among women breastfeeding (~50%) gens or DMDs. was much lower than for those not breastfeeding (>80%) (Portaccio et al., *Neurology* 2011)

Will I have more relapses after my child is

POSSIBLY. Following delivery, the situation that seems to protect a pregnant woman is reversed: and stage at which the pregnancy occurs (Vukusic Th1 increases and Th2 decreases, which correlates et al., *Brain*, 2004). with increased risk of relapse. Today, physicians are better able to predict who is at risk of post- How soon should I restart treatment? partum relapse, which appears to be linked to three **IT DEPENDS.** Generally, restarting treatment is factors: a) the number of relapses in previous years; related to the severity of MS. It is important to note b) the number of relapses during pregnancy; and c) that women who restart treatment must discontinue the degree of disability at the onset of pregnancy breastfeeding.

feeding, the decision to treat or not should be taken together with the doctor. If treatment is to be pursued, the patient should stop breastfeeding.

in a larger follow-up study (Airas et al., *Neurology*, Trials are ongoing to assess the possibility of pre-2010). The decision to breastfeed appears to venting post-partum attacks through the use of be associated with a milder disease activity; the steroids, (intravenous immunoglobulin (IVIG), estro-

Will my MS worsen following delivery of my child?

NO. Studies indicate that deterioration post-partum and two years following is not beyond what is expected in the course of MS in relation to the type



Progress in remyelination research

Catherine Lubetzki, Prof. of Neurology, Hôpital Pitié-Salpêtrière, France

that forms an insulating sheath (myelin sheath) around remyelination in patients with MS. nerve fibres. It is crucial to the protection of axons in In 1981 K.J. Smith and W.I. McDonald found that the central nervous system (CNS) and necessary to remyelination could restore rapid conduction of the rapid transmission of electrical impulses from one electrical impulses. nerve to another. When demyelination occurs, the "slot" of missing myelin causes the nerve to miss-fire From 2000-2008 - The groups of B. Blake-- or not to fire at all. In MS, the loss of messaging more (in experimental models) and of H. Lassbetween axons leads to clinical symptoms and the mann (in MS tissue) confirmed that myelin loss of axons (due to the loss of the myelin protection,) protects axons from degeneration. Therefore, releads to increased disability. The symptoms depend myelination leads to protection against disability. on the location of the demyelination.

Remyelination studies

Historically, it was believed that damage to the myelin sheath could not be repaired. Over the past 50 years, research has confirmed that remyelination does occur how it can be stimulated.

In 1961 Bunge and others reported the first evidence that remyelination occurs spontaneously, along with seen in the spinal cord of an adult cat.

Myelin is a white membrane (80% lipid and 20% protein) In 1965 Perier and Gregoire found evidence of the first

How does remyelination occur?

Once the possibility of remyelination was confirmed, the logical question was to ask: *How does it occur?* Further research shows that three types of cells are involved, each acting in different areas of the naturally, which ultimately prompted investigation into body. Each shows different potential to promote remyelination, in terms of both rate and zone.

Progenitor cells are a sub-set of cells that are not fully formed and, like stem cells, have the ability recovery of the impulses that had been lost. This was to differentiate into diverse adult cells. The most important difference is that stem cells can replicate

Inhibitors: various research groups are trying to develop compounds that promote remyelination. One Schwann cells are a type of glial cell that form the of the most interesting and advanced is associated myelin sheath in the peripheral nervous system (PNS). with Lingo-1, a natural protein in the brain and spinal There is evidence that Schwann cells might contribute cord that inhibits oligodendrocyte maturation and

a limited number of times. Progenitor cells are found areas of the CNS. in the sub-ventricular region of the brain and can Why does remyelination fail in MS? definitely contribute to remyelination, but within a very Seeing that this possibility for remyelination exists, limited region of the brain.

the myelin sheath. **Oligodendrocytes precursor** the area surrounding the lesion. cells are now considered as the main contributors to remyelination in the adult CNS.

indefinitely, whereas progenitor cells can divide only to remyelination in the spinal cord, but not in other

we want to understand why it fails in MS. For this, we must first understand the different steps of Oligodendrocytes precursor cells are immature the remyelination process. At present, all of this cells that persist in the adult CNS. They were ignored knowledge derives from experimental studies, both in for many years because there was no marker to vivo and in vitro. The main steps of the repair process identify them. Today, we know that oligodendrocyte are: recruitment of oligodendrocyte precursor precursor cells account for 5% to 8% of all adult cells to the demyelinated plaque; maturation into CNS cells, and that they are found throughout the oligodendrocytes; and wrapping new myelin sheaths CNS, both in the brain and in the spinal cord. After along the denuded axons. In general, two main demyelination, they are attracted to the damaged approaches for therapy have arisen from recent area of the brain or spinal cord: once they establish research: 1) finding ways to inhibit activity that blocks contact with the nerve fibre, they can develop into naturally occurring remyelination; and 2) transplanting oligodendrocytes, which are the cells that make up cells (stem cells) that can develop into myelin cells in





therefore prevents remyelination. Researchers are trying to develop compounds that inhibit production of Lingo-1. Some of these have been shown to be effective in experimental models. Phase 2 trials will begin soon, but it will be some time before this therapy is proven and available to patients.

Transplantation: efforts to transplant stem cells have been tried using cells from bone marrow, from the peripheral nervous system, and from other sources. Five aspects of this line of research are of note:

- Hematopoietoc stem cells (HSC) therapy leads to profound immunosuppression, but makes no contribution to repair (remyelination).
- Therapy using stromal cells also acts by modulating the immune system, however without demonstrated repair function
- Schwann cells can be transplanted to stimulate remyelination, but they do not migrate within the CNS, so their effect is limited in regional scope.
- Neural stem cells also have an immune-modulatory

(bystander effect) by favouring endogenous remyelination. However, their accessibility might be a concern.


- Stem cells from other sources:
- Olfactory ensheathing cells (OECs) are found in the lining of the nose. Although they do not form myelin in normal conditions, when transplanted to the area of a demyelinated lesion, they are able to remyelinate.
- Boundary cap (BC) cells are located at the interface between the central and peripheral nervous systems during development. Early studies show that BC cells are highly mobile and have a strong potential for stimulating remyelination.

At which stage of MS is remyelination effective?

As demyelination is an ongoing process in MS, it is valid to examine when treatment aimed at remyelination would be most effective: This is still an open question. In concluding, I wish to say a few words about the need to have hope role and might participate to repair indirectly as research advances in various areas of MS

therapy – and yet be cognisant of the need for scientific proof that therapies are effective. Even if we are some years away from having a therapy to offer from the current work in endogenous remyelination, recent progress targeting inhibitors of remyelination is very encouraging.

The same is true of stem cell therapy, which is still in quite early stages of investigation. It is important for people with MS to understand that much more academic investigation is needed in this area. Stem cell clinics are currently selling something other than effective treatment: they are offering only hope and illusion. They say that they cure everything, but they are doing it for money, not for science.





Cannabis in the Management of MS Symptoms

progresses despite available treatment to reduce *Pract* 2005;59: 291-95). its impacts, and many patients judge the current treatments as unsatisfactory.

that physicians use to measure the degree reported high levels of tetrahydrocannabinol of spasticity, but it has limitations in terms of (THC; the psychoactive cannabinoid) and low sensitivity, reliability and validity. The Numerical levels of cannabidiol (CBD; the anti-psychotic Rating Scale offers an alternative and more cannabinoid). Moreover, it is also known that reliable method in which patients rate their own smoking cannabis increases the risk of lung symptoms (on a scale of 1-10) for each 24-hour cancer, heart disease, etc., and that the substance period.

Spasticity, like all MS symptoms, occurs as a use as both a medicine and a recreational drug. result of myelin and nerve fibre degradation. It Medicinally, street cannabis has been used for ranks seventh of the top 10 symptoms of MS: its anti-spastic, muscle relaxant and pain relief 82% of patients report experiencing spasticity, effects. In a UK survey of persons using cannabis among which 54% say the symptom is moderate medicinally (mostly smokers) between 1998 and to severe. It is one of the most disabling 2002, almost 75% indicated that it was better or symptoms, and one of the greatest unmet needs somewhat better than their previous treatment for in symptomatic treatment. At present, spasticity MS or various pain states (Ware et al. Int J Clin

Apart from the associated legal issues, use of street cannabis raises other concerns. It lacks The Ashworth Scale is the most common tool standardisation and purity and recent samples has variable pharmacokinetics that cause very high THC peaks, which lead to psychoactivity Recently, there has been increased interest in and other adverse events (Chong et al. Mult the use of cannabinoids to treat spasticity in MS. Scler 2006; 12: 646-51; Wade et al. Mult Scler Cannabis (*Cannabis sativa*) has a long history of 2006; g12: 639-45; Aldington et al. *Eur Resp J*

Ashworth scale is the most commonly used scale to measure spasticity

Score Modified Ashworth Scale

No increase in muscle tone

Slight increase in muscle tone, manifested by a catch and release or by minimal esistance at the end of the range of motion when the affected part(s) is moved in flexion or extension Slight increase in muscle tone, manifested by a catch, followed by minimal resistance throughout the remainder (less than half) of the range of movement (ROM) More marked increase in muscle tone through most of the ROM, but affected part(s) easily moved Considerable increase in muscle tone, passive movement difficult

Affected part(s) rigid in flexion or extension


• Limitations: lack of sensitivity, reliability and validity

2008; 31: 280-86.; Potter et al. J Forensic Sci high levels of cannabidiol (CBD). These two 2008; 53; 90-4).

These concerns prompted the development of comprises minor cannabinoids, terpenoids, cannabis-based pharmaceuticals. A key aim was sterols and triglycerides. to produce a standardised medicinal product based upon the main active constituents of Endocannabinoids are "Retrograde" Neuromodu-*Cannabis sativa:* tetrahydrocannabinol (THC) and lators – i.e. they are released from post-synaptic cannabidiol (CBD). Under controlled conditions, neurons and act at cannabinoid CB, receptors the substance can be formulated to ensure on pre-synaptic axon terminals. THC links to purity and stability. As an alternative to smoking, both CB, and CB, receptors, showing greater the therapy was developed to be administered activity at CB, subtypes (which may account through an oral/nasal spray (oromucosal) that for its psychoactivity). CBD has lower affinity for provides a satisfactory pharmacokinetic effect both receptors and is an antagonist at the CB, while avoiding the high plasma levels and risks receptor. Thus, CBD may act synergistically with associated with smoking. This approach allows THC to antagonise psychoactive and sedative the benefit of the synergistic interaction between effects while enhancing cannabinoid-mediated CBD and THC, with reduced psycho-activity and clinical effects. The two active ingredients, which enhanced cannabinoid-mediated clinical effects. are absorbed and appear in the plasma within 15 Looking particularly at the drug Sativex, it is minutes, have complementary effects: (see table). prepared from two cloned chemovars of C. sativa to ensure standardisation and quality. One clone produces high levels of 9-deltatetrahydrocannabinol (THC) and the other


cannabinoids account for about 70% of the composition of Sativex; the remaining 30%

Maximum plasma THC levels with Sativex and Street Cannabis (smoked)



THC	CBD
Antiemetic	Analgesic
Analgesic	Anti-convulsant
Muscle relaxant	Anti-psychotic
Appetite stimulant	Anxiolytic
Psychoactive	Neuroprotective
Russo & Guy Med Hypotheses 2006; 66: 234-46.	

Sativex third pivotal clinical trial: two-phase study design



of effect, which highlights the importance of across Europe and included additional secondary tailoring dose amounts. The cannabinoids are outcome measures such as the timed 10-m quickly absorbed into body fat, but plasma walk, the Berthel ADL index, the Carer's global concentrations following oral/nasal spraying impression of change, quality of life, and safety are lower than those after inhalation because and tolerability. Again using the NRS, patients absorption is slower and redistribution into fat is improved by ≥30% (from baseline) and also scored rapid. The falling off of the effect happens in two improvements on other symptoms: fatigue (51%); phases; the initial effect falls off within about four spasm (76%); bladder (73%); tremor (80%); pain hours and the substance is fully metabolised (by (76%) and sleep (61%). the liver) within 24 to 36 hours.

United Kingdom and Romania, included 189 a ≥30% improvement. The measures of quality patients and assessed (as the primary outcome) of life improvement were significant in this study: the change in severity of spasticity using the higher scores on the Berthel scale of activities of Numerical Rating Scale. Secondary outcomes daily living; patients, carers and physicians noted included the Ashworth scale, the motricity index, higher global impressions of change; less sleep daily mean spasm scores and the patient's global disruption; lower spasm frequency; and higher impression of change (Collin C et al. *Eur J Neurol* quality of life scores (Ambler et al. *Mult Scler* 2007; 14: 290-96). NRS scores were shown to 2009; 15: S258; Montalbán & Wright Mult Scler be reduced by about 50%, with patients reporting 2009; 15: S272). an improvement of \geq 30% (from a baseline).

Patients experience somewhat different degrees A second, wider clinical trial had 337 participants

A third trial expanded to include 572 patients in The first clinical trial of Sativex, carried out in the a two-phase study, with results again showing



assessed patients who remained in the study side effects typically associated with recreational evidence of the short- and long-term efficacy for at least one year: symptom scores remained cannabis use (Wade et al. Mult Scler 2004; 10: of Sativex in MS-related spasticity, with half of significantly lower with Sativex than baseline 434-41; Wade et al. *Mult Scler* 2006; 12: 639- patients clearly receiving benefit from this add-on values. For example: spasticity was scored at 45; Collin et al. *Eur J Neurol* 2007; 14:290-96; treatment. 69.5 (0 weeks), 34.2 (10 weeks) and 31.8 (82 Collin et al. *Mult Scler* 2007; 13: S129; Ambler et weeks). Of 25 patients who interrupted treatment al. *Mult Scler* 2009; 15: S258). for two weeks, 20% needed to resume Sativex before the end of 14 days due to re-emergence There is no evidence from these randomised improvement in symptoms.

gradual "up titration" schedule was introduced, there is no evidence of drug misuse or abuse. the incidence of AEs declined. Overall, the rate of withdrawal from the trials due to AFs was

of marked symptoms. During the interruption clinical trials (RCTs) that Sativex poses any longperiod, seven patients reported that their MS term or irreversible neuropsychiatric or cognitive symptoms were much worse, 10 said that they risk to patients. The potential for abuse of Sativex were worse, 5 the same and 3 reported an is quite low, in part because the drug does not exhibit the psychostimulant effects typically associated with recreational cannabis use. Any It is important to examine the adverse effects sense of iintoxication was reported to be very low (AEs) of Sativex. During the first four weeks during the course of short- and long-term studies. of exposure, the most common effects were Sativex has not been associated with signs of dizziness (14% to 32%) and fatigue (12% to 25%); drug tolerance and in a long-term trial the mean both were usually reported as mild to moderate dosage decreased slightly. Finally, no consistent and resolved quickly. When the recommended withdrawal syndrome has been observed, and

A subsequent long-term, follow-up study low. Importantly, Sativex does not exhibit the Results from controlled RCTs provide conclusive



Threats to Adequate MS Treatment in Portugal

everyone in Portugal, with costs being covered announced, 39 guidelines have been issued (with by the National Health Service (NHS) network. a target for 50 before the end of the year) and Hospitals and health centres provided services the pharmaceutial market in Portugal has been for people seeking treatment, regardless of their forced to reduce retail prices by 20% (compared income or the health situation.

the treatment of PwMS.

The NHS is has been given targets to reduce the share of health budget within gross national In recent years, treatment of MS in Portugal has product (GNP) by 1.25% in 2012 and a further 1% been state of the art. Of an estimated 5,000 in 2013. Over the period 2010-13, this equates to PwMS, more than 3,500 were actively being a 40% reduction in costs within the NHS itself. treated. Once early symptoms were identified In 2012 alone, the health budget has been cut by a general practioner, patients were quickly by EUR 800 million. Cuts are already evident on referred to opthalmologists or neurologists, or street pharmacy profit margins (many pharmacies to other members of a network of highly skilled are closing) and in the fact that guidelines and MS specialists. MS nurses have played a very central purchasing plans for hospital products important role in education, training and managing (including oncology, AIDS and MS) are targeting patients.

Before mid-2011, health care was almost free for a 15% savings. Six months after the reforms were to Aug 2011) (IMS Health).

Due to the economic crisis, the newly elected In 2012, the average street pharmacy will show a government took strong steps towards making negativeprofit of €39,891 and a negative operating drastic cuts in state expenditure in all areas. This income of -€739. Expenditure on staff will has affected the health budget and, accordingly, represent 17.2% of sales value and 57% of total costs. It is expected that about 1,200 pharmacies will close in 2012, with a net loss at all levels.

MS Treatment – State of the Art

Patient Associations

SPEM – Sociedade Portuguesa de Esclerose Múltipla ANEM – Associação Nacional de Esclerose Múltipla TEM – Todos com a Esclerose Multipla

- Medical Society
- GEEM Grupo de Estudos de Esclerose Múltipla

Treatment Centers

34 in 42 hospitals have MS Department 4 main hospitals:

- S. João Oporto
- CHUC Coimbra
- Sta. Maria Lisbon
- Hosp. Capuchos Lisbon

Medications available (100% reimbursed) Interf Beta 1a – Avonex / Rebif Interf Beta 1 b – Extavia / Betaferon Copaxone Tysabri Gylenia

- MS Consensus under development
- National Commission was created to validate MS Centers and patient treatment (current and newly-diagnosed patients)
- Increased pressure on HCP to reduce or minimize treatment costs.

SPEM

- Increase co-payment for medical assistance
- Reduce access to treatment (MRI, patient transportation)

Since the reforms, the MS Society has noted some substantial changes, even though the fundamental mechanism of prices being settled by the Minister of Economy and Regulatory Authorities remains unchanged.

Before	Today
SPMS (National Purchase) set tenders based on price and/or national guidelines	 SPMS (National Purchase) set tenders based only on price; national guidelines have been eliminated
MS specialist prescribed treatment based on patient needs / patients had free access to treatment and prescriptions	 Hospitals are creating sub-groups to select products based only on price and own clinical criteria; these clinical criteria could be different from region to region
 Hospitals purchased medication from pharma companies based on SPMS catalog and supplied patients through hospital pharmacies 	 Only two products (one 1st-line; one 2nd-line) will be available for patients
	 No more free prescriptions If the prescription is different from what hospital provides according to administration guidelines, it will have to be approved by the pharmacy commission
	• Difficulties in accessing treatment are increasing. For example, access to MRI is reduced, which increases difficulties in obtaining a diagnosis. Hospital pharmacies are delivering DMDs for only one week of treatment, instead of the usual one month.

The guideline that hospital pharmacies should deliver only one week (rather than one month) of DMD therapy aims, in part, to avoid the loss of drugs that occurs when patients abandon the treatment. Under the new guideline, only 1 week is lost in such cases. But the guideline is very disadvantageous for people who live far away from hospitals: the time and cost associated with the weekly trip fall to the patient's family, not on the government's budget.

Several fundamental problems are evident in the new model. With no national guidelines in place, decision making takes place locally and is inconsistent, often based only on price considerations. Difficulties in accessing MRI have a negative impact on diagnosis. Limitations on therapeutic options have effectively transferred the important role of the physican making the best decision for each patient to the hospital's administrative authorities: neither physician decisions nor patient needs are adquately respected. Ultimately, reduced access to treatment increases the risk of more rapid disease progression for patients.



Empowerment Case for Poland

Luiza Wieczyńska, Deputy CEO, MS Society of Poland (PSTR)

Poland has consistently been placed among the 2011, the Group has met six times (organised lowest-ranking countries in Europe. In 2011, by the PSTR) and has written numerous letters Poland achieved a score of just 87 points out of and undertaken various interpellations such as a possible 225 - precisely 140 points below the supporting PTSR initiative to change the rules first-placed Germany. But such comparisons are restricting the therapy access. only one aspect of the MS Barometer; the other benefit of the tool is that it facilitates measurement Intense lobbying efforts of the PSTR, including very little change: in 2009, Poland scored 79.

areas in which Poland attains a low score (22/70), was eliminated. These advances still fall short of placed sixth from the bottom). But somewhat reflecting the recommendation of the European surprisingly, Poland ranks 14th from the top in Code of Good Practice in MS, which states that terms of empowerment of PwMS and has seen treatment should be continued as long as benefit substantial progress in the past two years - rising is evident. Such hard-won progress in the right from a score of 8 in 2009 (of a possible 35) to 18 direction is cause for celebration, but one must in 2011. The key achievement is that PwMS are not overlook the reality that each PwMS in Poland now represented in the MS Parliamentary Group. has to face not only the disease, but a restrictive This consultation group comprises 13 Members policy environment. of Parliament from diverse political backgrounds For this reason, the Medical Advisory Board of the but united by a common interest: improving PSTR undertook (in 2005) to develop a National

Since EMSP launched the MS Barometer in 2008, the situation of PwMS. Since it was established

of year-to-year progress within a given country. the hosting with EMSP (in 2011) of a High-Level Unfortunately, even on this scale Poland has seen Roundtable, have also been empowering for the Society and for PwMS. Last year, the limitation on access to DMDs was extended from 3 years to Access to the latest MS therapies is among the 5 years, and an age restriction for those over 50



Therapy Plan (NTP), which closely follows the Code of Good Practice in terms of content and includes a detailed budget (updated annually). The Plan is multidisciplinary and emphasises the importance of multiple tasks in the course of treatment: disease-modifying therapy, rehabilitation, symptomatic treatment, the establishment of a national registry, etc. It aims to provide a comprehensive and professional system of care for PwMS. In 2012, the PSTR will update the content of Plan to reflect new treatments that have become available.

The Plan aims to see 500 new PwMS gaining access to DMDs each year, and to ensure that all those being treated receive an MRI annually to assess disease progression. Importantly, the Plan also calls for the opportunity for PwMS to change drugs during treatment if they find that one is not as effective as hoped or causes intolerable sideeffects. Finally, the Plan calls for workshops and trainings for neurologists, nurses, rehabilitation experts and other MS specialists.





A "Starting Point" for Living with MS

avstamp, the name selected for an educational programme for newly diagnosed PwMS, carries a strong sense of forward momentum: it translates as "starting point", "kick-off" or "take-off". The programme was launched by the Swedish Association for Persons with Neurological Disabilities (NHR) in response to a survey (2004) showing that many PwMS felt poorly informed following their diagnosis.

The avstamp programme aims to provide accurate information and give PwMS an opportunity to meet informally with experts and others who are newly diagnosed. NHR works closely with the Neurology Clinic, particularly MS nurses who play the critical role of identifying and inviting PwMS to attend avstamp events. Normally, participation is limited to about 12 people to provide a comfortable degree of intimacy.

The programme is delivered over four evening sessions, covering four aspects of living with MS with relevant experts giving presentations and leading the discussion:

- What is happening in mybody? Lecturers: Neurologist + MS Nurse
- Psychological aspects and society's responsibility Lecturer: Psychologist + Welfare Officer
- Living with MS in daily life Lecturer: Physical Therapist + Occupational Therapist
- 4th evening: A separate lecture for family and friends

The final evening is an important opportunity to explore how MS affects family life. NHR finds that most PwMS bring at least three family members to this evening, confirming that the disease touches evervone.

NHR feels programmes like **avstamp** should be a priority: many newly diagnosed patients feel that early treatment focuses solely on getting access to the right drugs. avstamp provides an opportunity to explore other topics important to coping with the reality that one has a life-changing disease.

avstamp is offered regularly in 15 centres across Sweden, However, NHR recognises that not

everyone can attend in person. Thus, in 2012, the Association will launch an online version of the programme that anyone can access. The site specifically encourages those who visit to establish personal contact with other PwMS to share learning and experiences.

NHR was established in 1957 as an MS Society. Today, it represents a broader range of neurological disabilities and has approximately 13,000 members, of which 60% have MS. NHR offers services through 96 local branches throughout Sweden.

avstamp: Project history

- In a 2004 survey, 149 members were asked how their need for information was fulfilled:
- 59% were not satisfied with the information given from the clinics when they were newly diagnosed
- 72% claimed to be left on their own collecting information after getting their diagnosis
- NHR was often said to be the most important information provider

National political developments in health and social care since 2003 in Serbia



Serbia (excluding Kosovo) has population of 7.1 system was very fragmented, which had a negative million people, which is declining as the death influence on the continuity of care. Services were rate (13.85/1,000 people) exceeds the birth rate marred by low efficiency and uneven quality, (9.19/1,000) and the fertility rate for women is 1.4. and by a lack of motivation to engage in health The median age is currently 41.3 years; average promotion and disease prevention. Attempts to life expectancy is 71.49 for men and 77.34 for include health consumers in primary health care women. Health expenditure accounts for 9.9% (PHC) policy decisions were taken with a nonof GDP and the physician ratio is 2.035/1,000 systematic approach and therefore of limited population.


of the Roma population is registered and many of doctors. do not have legal status. It should be noted, however, that in cases of emergency, health The reform has achieved several important services are provided to all in need.

value.

The national health system offers three levels In 2002, the government launched a reform of of care - primary, secondary and tertiary - and the healthcare system based on a report entitled operates on a principle of universal access, with Health Care Policy: The Vision of Health Care all costs being covered by the national health System Development. A 2006 analysis noted institution. However, to obtain care, an individual the development of a network of PHC institutions must obtain a health card, which requires (comprising 158 PHC centres) and stated that registration of the place of residence. A key 36% of all doctors work in PHC, with general challenge in this regard is that a very low portion practitioners making up 17% of the total number

aims, including a better definition of healthcare In 2001, the Serbian healthcare system was institutions according to the healthcare levels. At functioning poorly on several levels. Overall, the the individual level, the chosen doctor concept

Health-care system in Serbia




Health-related strategies of the Republic of Serbia

- Poverty reduction strategy paper (2003)
- Action plan for children (2004)
- Action plan for health of Roma population (2005)
- Strategy for elder population (2005)
- National Strategy for Fight Against HIV/AIDS (2005)
- Strategy for Youth Development and Health in the Republic of Serbia (2006)
- Tobacco Control Strategy (2007)
- Strategy for the Development of Mental Health Care (2007)
- Strategy on Occupational Safety and Health (2009)

 Program for Protection of the Population from Communicable Diseases 2002 -2010 (2002)

- Program for Protection of the Population from Tuberculosis (2005)

- The Strategy for Continuous Improvement of the Quality of Health Care and Patients' Safety. The Strategy for Prevention and Control of Non-communicable Diseases. The Strategy for Palliative Care, The Strategy for the Fight against Drugs...



separation of the specialist-consultant service. Commission noted progress in many areas, Local communities became more vested in the ownership of the PHC centres and management been implemented. In response, the Serbian of PHC institutions was largely decentralised. Importantly, preventative centres were developed through a European Agency for Reconstruction project for Improving Preventive Health Services in Serbia. Serbia also received funding from the Canadian International Development Agency (CIDA) to support the PHC system development (Balkans Primary Health Care Policy Project).

Building on these achievements, Serbia is now focused on the implementation of a Strategy and Action Plan of the Health Care System Reform until 2015, which is based on numerous documents published in the past 10 years, as well as on legislation enacted at national and local levels.

The reforms aim to improve health care for all, starting with a clear vision and advancing to a strategy and action plan The 2010 Serbia

was introduced, which also facilitated the Progress Report, prepared by the European but also identified those in which plans had not government has prepared a new strategic document. Serbia 2020, which sets out two main goals:

- To define the framework for the Republic's socio-• economic development up to 2020.
- To continue reforms in the sphere of health care, both in terms of finance and management of the system, with the strategic goal of improving the quality of health of all citizens, especially children and vulnerable groups.

Serbia acknowledges the high value of cooperation with NGOs and aid organisations in working toward these goals.

Complementary to the health care reform, Serbia has also made substantial progress in five areas of social care: developing a strategy for social care; introducing new social welfare law and sublaws; establishing a social protection chamber; deinstitutionalising children with disabilities; and



Legal basis for system development and health care reform

System laws:

By-laws and sub-laws (about 40 based on system laws):

- Health Care Law (2005)
- Health Insurance Law (2005) Medical Chambers Law
- (2005)
- Law on Drugs and Medical Devices (2010)

Law for communicable diseases

- Law on sanitary inspection
- Regulations based on the Law on Medicines
- Red Cross Law
- Regulation on Co-payment fees (personal contribution of the insured population in health care expenses)
- Network of health institutions
- Continuous Quality Improvement
- Licensing, accreditation and CME

intersectoral committees for additional support for as the sub-law on community service standards, children with disabilities (social care, health and which was developed through consultations with education).

A strategy plan launched in 2005 focused on establishing a network of community-based social care services (instead of social care institutions). It also sought to transform residential social institutions and decentralise social care services and institutions. This effort was based on 130 In undertaking health and social reform in parallel. local social care strategies; by 2008, Serbia had and establishing clear priorities in both areas, achieved a re-organisation of centres for social protection, including the implementation of new standards and regulations.

The Social Welfare Law adopted in Parliament on 31 March 2011 (applied since 12 April 2011) represents experienced limited access to education and the Serbian law, be purchased by the NHI Fund the largest shift and most "pro-poor" and "pro-financial assistance. inclusion" legislative change the welfare system has introduced over the last decade. It legitimises It goes without saying that people with MS fit the strategies developed since 2000 (e.g. Poverty into this group of vulnerable persons. The MS Reduction Strategy and Strategy for Development Centre at the Clinic of Neurology, Clinical Centre administrators rather than their treating physicians. of Social Protection) and mainstreams many donor of Serbia (Belgrade) estimates that there are 6,000 and pilot reform initiatives implemented. The new PwMS in the country. The main problem is limited

promoting cross-sectoral cooperation, including law is complemented by several sub-laws, such social protection stakeholders and is aimed to be adopted by the end of 2012.

> The social protection chamber establishes ethical regulations and oversees licensing for social care professionals.

Serbia has taken an important step towards a more holistic approach to the overall well-being of A specific issue exists in Serbia regarding the IFNits citizens – particularly those in vulnerable groups. Historically, the poor and disabled in Serbia have (Avonex and Rebif) have the same International faced discrimination and unemployment, and Nonproprietary Name (INN) and must, under

access to disease-modifying drugs (DMDs), which have only been available in Serbia since 2005. At present, only about 550 PwMS in Serbia are treated with DMDs (263 with interferon (IFN)-beta 1b, 260 with IFN-beta 1a, and 23 with glatiramer acetate). Due to very limited financial resources, the National Health Insurance (NHI) Fund restricts access to these drugs: a special expert committee in each MS Centre selects priority patients. There is an ongoing need to work with MS Societies to increase pressure to NHI to fund therapy and to raise public awareness.

beta 1a treatment. Two IFN-beta 1a preparations on the *either/or* basis. Under this scenario, the law stipulates that the less costly drug must be purchased. This situation places decision making about patients into the hands of health



Recent Developments in Patient Involvement in the EMA

Lise Murphy, co-chair of the PCWP and a patient representative of EURORDIS

and Christoph Thalheim, EMSP representative at PCWP

During the period 2007 to 2010, patient Assessment Committee (PRAC). involvement in activities at the European As those who live with disease, patients provide In 2009 and 2010, patients were involved in Medicines Agency expanded substantially - invaluable contributions to the review of product reviewing about 60 European Public Assessment from just 76 patients participating to more than information, including EPAR summaries, package 300 interventions. Patients became active in leaflets and safety information (Q&As). Their ad- Of particular importance to PwMS was the Scientific Advisory Group (SAG) meetings, safety hoc collaboration in the CHMP supports input opportunity to have a voice in EMA activities communications, consultations for both the on product assessment and the preparation of related to Tysabri, Famprya and a transatlantic Committee for Medicinal Products for Human Use guidelines. (CHMP) and the Scientific Advice Working Party particularly important deveopment has been the turning point in the level of patient involvement.

Products (COMP), the Paediatric Committee EnprEMA - is equally important.

areas of scientific advice/protocol. Involvement in having a voice in regulatory matters. The positive recognition of patients as "experts" in high-level other initiatives – such as the European Network impacts are evident in both quantity and quality meetings. A noted below, 2010 marked a real of Centres for Pharmacoepidemiology and of outputs. Based on the success of the EMA Pharmacovigilance (ENCEPP), Eudravigilance model of working with patients and consumers, (a data-processing network and management a similar initiative was launched by the Heads of Patients now serve the EMA in many roles. system for reporting and evaluating suspected Medicines Agency (HMA)¹ in April 2011. Some act as full members of the Management adverse reactions), and the European Network of To further enhance the role of patient experts, Board (MB), the Committee for Orphan Medicinal Paediatric Research at the European Medicines the EMA recognises the need to expand the

(CAT) or the Patients and Consumers Working through the Working Party with Patients' and "EMA literacy training" to help patients better Party (PCWP). Others play a role as Observers of Consumers' Organisations (PCWP), which understand complex issues. the Pharmacovigilance Working Party (PhVWP) focuses on improving transparency, information and, from July 2012, the Pharmacovigilance Risk on medicines, pharmacovigilence and interaction

with scientific committees.

Reports (EPARs) and over 130 package leaflets. workshop on PML.

The EMA reports that both patients and (SAWP), and in workshops and conferences. A Their experience is also valuable to experts in the consumers see the benefits of being involved and

patient networks at the national level (which (PDCO), the Committee for Advanced Therapies EMSP is pleased to be involved in EMA activities requires additional resources) and to provide

> 1) The HMA is a network of the Heads of the National Competent Authorities whose organisations are responsible for the regulation of Medicinal Products for human and veterinary use in the European Economic Area.

Workshop A | EUReMS: Background, **Structure and Expected Outcomes**

Dr. Jaume Sastre-Garriga, CEM-Cat, Barcelona and Dr. Tsveta Schyns-Liharska, EMSP

European patients, including PwMS, face huge The vision for EUReMS is to: inequalities in terms of access to treatments and care, guality of life, etc. They also live under a wide range of socio-economic factors: geographic location, living and working conditions, education, income, etc. In a Europe built on values such as solidarity and equity, this is unacceptable.

At present, this situation is exacerbated by a widely recognised lack of data on: disease epidemiology (including age- and gender-specific trends); access to disease-modifying and symptomatic treatments; long-term efficacy, safety and costeffectiveness of DMDs; societal costs and how to best allocate socioeconomic resources; degree of access to health care services and their quality; years, important milestones are set out to develop and the quality of life priorities of PwMS.

By developing the European Register for MS (EUReMS), EMSP aims to both enhance the data and information available about individual PwMS and the entire MS community across Europe.

- provide the infrastructure for data collection, data analysis, interpretation and dissemination of results in MS with European cross-border validity;
- serve as a tool for epidemiological surveillance of MS in Europe: and
- ultimately support PwMS and their carers in their daily lives as well as MS health professionals and the scientific MS community at large.

EUReMS is truly European in scope and multidisciplinary in its approach, involving experts from patient organisations, the clinical community, universities in many countries, as well as various pan-European organisations. Over the next three and test the register, with the aim of using it to help design new research projects by 2014.



Workshop B | Certified Online Training for MS Nurses in Europe

Anne Winslow, EMSP Vice-President

2011), EMSP has been leading a pan-European relationship between neurologists and patients initiative to enhance recognition of the role of MS establishes mechanisms and links to enhance nurses and to unify their knowledge and expertise care, and thus outcomes. The MS-NEED survey through certified training. A key aspect of this found that MS nurses play a central role in the project is the online delivery of training, which long-term treatment of PwMS and often provide broadens access and is well-tailored to individuals significant support, which has a positive effect on who are already working as professional nurses. both coping and compliance. The presence of an Increasingly, both health professionals and MS MS nurse significantly reduces the neurologist's patients acknowledge the key role MS nurses workload and is also cost-effective for health can play within a multi-disciplinary team (MDT). systems.

Following the MS-NEED Survey (carried out in In fact, bringing MS nurses directly into the

The MS-NEED Survey identified three key findings and set relevant recommendations:

Finding	Recommendation
Role of MS nurses is evolving and expanding	Recognise MS nursing as a specialty across Europe
Best practice sharing can enhance MS nurses' role within the MDT	 Need for shared MS nursing educational events/opportunities/resources across Europe in range of settings that include web technology & social media Ensure there is a structured, formalised and improved partnership working within current European forums and international organisations
Tools and education are needed	Need for a stepwise professional development structure against an agreed European definition for MS nursing



The pan-European unification of MS nurses will increase quality of care for people with MS and their families, and will also directly address the European Commission's Green Paper: Modernising the Professional Qualifications Directive (2005/36/EC) - focused on preparing for mutual recognition of a national degree (such as an MS nurse exam) across all member states.

The MS Nursing Project is a collaborative effort of EMSP, Rehabilitation in MS (RIMS) and the International Organisation of MS Nurses (IOMSN).









Workshop C | MS Barometer and UNDER PRESSURE: Living with MS in Europe

Elisabeth Kasilingam, Marilyn Smith, Walter Astrada, Fernando Moleres, Lurdes Basolí, Maximiliano Braun, Carlos Spottorno and Jesús Mora López-Almodovar (PwMS)

independent living.

In the autumn and winter of 2011/12, a team of of low disability pensions. five photojournalists travelled to 12 countries¹ to capture how health and social policy influences By contrast, MS-félag Íslands (MS Society of - for better or worse - the daily lives of PwMS. Iceland) is able - through government support - to The team worked closely with the MS societies, operate a day centre that can accommodate 40 and was thus able to identify individuals whose PwMS each day. Aside from providing services situation reflects the positive and negative ranging from rehabilitation to psychotherapy, the aspects of each country.

proundly negative impact of inadequate policy remarkable for its accessibility legislation, which in Belarus and the ways in which policies that makes it easy for PwMS to travel on electric support independent living empower PwMS in scooters or in wheelchairs. Iceland and Germany.

Despite advances in some areas in some The MS Society of Belarus estimates that 500 countries, overall the MS Barometer results of PwMS live in the capital city of Minsk. None 2011 show a downward trend against 2009. have access to DMDs or to rehabilitation, and What is unchanged is that huge discrepancies many reach advanced stages of disability at very exist among countries, which means that a young ages. Moreover, Soviet-style apartments large number of PwMS in Europe do not have and poor infrastructure are substantial barriers the same opportunities for treatment, care and to mobility. The Society believes that about 430 of these people are rarely able to leave their apartments, and live in a state of poverty because

Centre has facilities for recreational activities. In many ways, it serves as a community Centre At the two extremes, the team saw first-hand the for PwMS living in Reykjavik. The city is equally





of access to therapies, and for the exceptional as a result of which European country they live rehabilitation programmes offered at the in. The photographers are united in their desire Quellenhof Centre. A large number of PwMS to use this project to bring media attention to the (primarily those with additional private health situation of PwMS across Europe. insurance) are eligible to spend 1 to 3 weeks at the Centre each year, where a multidisciplinary The project aims to launch various awarenessteam develops a programme that focuses on the raising products and activities in early 2013, to patient's current needs and personal goals.

Jesús Mora López-Almodovar told workshop drug shown to be effective for MS. attendees that he chose to participate in the UNDER PRESSURE project because he felt MS remains poorly understood by both the general public and by policy makers. Allowing everyone to see into his daily life is a way to send important messages that may help to improve the situation for fellow patients in Spain and across the European Union.

The photographers confirmed Jesus' perception: all admitted that before becoming involved in the project, they had very little exposure to MS. Now, they have friends with MS who are quite Kingdom.

Germany is equally noteworthy for its high-level likely to have very different quality of life, simply

help mark the 20th anniversary of the approval (by the US Food & Drug Administration) of the first

1| Belarus, Estonia, France, Germany, Greece, Iceland, Ireland, Italy, Poland, Spain, Romania and the United





Table of Contents

Introduction Emma Rogan Ireland	37
Sexuality and MS Marjan Netherlands	38
Pregnancy and MS Isabella Belgium	40
The Italian Experience Silvia and Federica Italy	43
Conclusion	45



Introduction

Carrying on the successful gatherings in 2010 and Chosen over the last twelve months through MS in her daily life as an individual, as a worker, 2011, the EMSP Youth Congress continues to be online collaboration and following on from as a partner and as a mother. an opportunity for representatives from all over previous years, the topics of Sexuality and Europe to share experiences, discuss different **Pregnancy when living with MS** were the issues. The film had a profound effect on many people issues and to create plans for positively changing for discussion in 2012. the experiences of Young People with Multiple Sclerosis (YPwMS) in their home countries and in YPwMS consider these issues very important to be an excellent way to open up the discussion Europe as a whole.

attendees from thirteen countries: Belgium, Czech affect us all on a deep, emotional level. Republic, Denmark, Estonia, France, Greece, Ireland, Italy, Lithuania, Netherlands, Norway, During the previous twelve months Julie Deléglise, group was seventeen women and one man. With with a group of people from the Youth Congress. main topics.

for their lives now and in the future. Discussing of topics that, due to cultural and social taboo, what are sometimes considered private, taboo many thought had been ignored and not treated Barcelona was the location for the third Youth topics in a clear and openhearted fashion was with enough consideration. Congress held on May 19th 2012. It was an a way to open up the dialogue for MS societies opportunity to reflect on the work done since across Europe. These are topics fundamentally This video is available at www.emsp.org the last two meetings of YPwMS and look to the important for all young people, straight, lesbian, future work of the group. There were eighteen gay, with or without MS and they are issues that

Romania and Spain. Gender composition of the EU Affairs and Membership Officer at EMSP, liased such a diverse gathering in terms of nationalities, Following guestionnaires, teleconference it was a fantastic opportunity to share different interviews and careful collaboration, a video cultural experiences particularly related to the about these issues was produced. Sexuality and **Pregnancy with MS** is a short film showing the experiences of a young woman as she deals with

at the Youth Congress - it was true to people's experiences as well as humorous - and proved





There are NO major sexual difficulties, only lack of imagination!

Sexuality and MS

Before starting to talk about sexuality we saw the movie "Sexuality, Pregnancy and MS". I invite you to watch it: www.emsp.org. We discovered the movie is a fantastic tool to start discussions about sexuality, pregnancy and MS. We all like to A lot of YPwMS seem to have problems with know about these subjects and enjoy a nice sex life, but to talk about sex...that is another story. It tension. Even the thoughts of having cramps was a significant film for many of the participants, during sex cause difficulties and are a common causing a profound effect because the characters problem. portrayed many of the issues faced in the daily reality of life as a YPwMS.

As sexuality is a difficult subject to talk about, we tried to get answers to the following questions:

- Which sexual changes (physical and psychological) do young people with MS have to face?
- How to cope with these changes?
- What are the strategies to better communicate with your partner, lover, friends, doctors, health care professionals, sexologists?
- to recover and enhance body image, self-worth and sexual confidence? to have a fulfilling sexual life (use of sex toys, dildos, lubricants, body



Relaxation and meditation could solve some of these problems.

mapping...)

Do national MS societies provide support and/or counselling to young people with MS regarding intimacy and sexuality?

fatigue, loss of sensitivity/sensibility, cramps and

Talking to your partner is a major issue. As problems are common when we have sex, they are not the same issues every time and might not be an issue at other times. MS can be a problem in a relationship, but do not make MS the most important thing in the relationship. We have discovered that partners of YPwMS are often forgotten. Partners may think that they are the problem, when actually it is other issues that are causing their partner with MS the difficulties. Without communication, it is very easy for our partners to misunderstand what the issues are and to know that they are not the cause of them.

Be careful if you look for advice on internet. There is plenty of information on the Internet. but there is a question of whether this information is always reliable.





Take it easy and relax!

Often, it is the lack of communication about the sexual health is often not discussed by health issues (fatigue, cramps, poor body image) that is professionals, YPwMS get the impression that the cause of sexual issues.

together. A quality weekend for the couple once a have the opportunity to fully discuss the impact month for instance. Children are out of the house. MS has on our sex lives. spending a lovely time at their grandparents, and creating a romantic atmosphere.

Being positive, having fun and enjoying the newsletter columns, on Facebook and their own pleasures of sex is very important and is something website. It was suggested that future workshops that needs to be planned. Having lunch in a nice about sexuality should be planned with other restaurant, walking in a park, swimming in the topics included. sea, go to the cinema and watch a nice movie, buy flowers...things that make the other person feel loved and special is a vital part of ensuring happens it happens, but it is all about a good the sexual aspects of a relationship are given time together. Look for ways to do the things you opportunities to flourish.

There are cultural as well as personal issues that might prevent people from talking about their sex lives to their neurologists, doctors, or other healthcare professionals. Also, because positive

it is not important. If healthcare professionals were willing to discuss the issues of sexuality and Of course we need to focus on a good life pregnancy, YPwMS would be more open and

> Our national MS societies provide some information about sexuality in brochures, small

> Love yourself and love each other. When sex enjoy most with the people you like the most!



Love yourself, know your body and use sex toys!





Don't be ashamed, talk openly to your partner about your feelings regarding having children.

Pregnancy and MS

"It's a paradox. How does one balance living in the now with preparing responsibly for the future? The key to this dilemma lies in the distinction between 'worrying about the future,' and 'preparing for the future.' The two concepts are not at all the same." Jonathan Lockwood Huie

To kick off this workshop, the 18 participants were asked whether they have children or not:

- There were three YPwMS with children:
- One YPwMS was five months pregnant;
- There was one man present in the group and his wife was pregnant;
- Some YPwMS had a dilemma about whether to Others were more difficult to discuss. We all have have children:
- have children.

Knowing this, I could finally begin to start the

• Due to treatment, do persons with MS face infertility?

- Is pregnancy causing new symptoms?
- Is pregnancy worsening the condition? To what ٠ extend?
- Do pregnant women with MS have to stop their treatment during their pregnancy?
- By choosing to have children, do people with MS feel guilty? Selfish? By choosing not to have children, do people with MS feel guilty/ selfish? What are their concerns?
- Where does research stand with MS and heredity?
- Strategies to communicate with the partner, the relatives, friends, doctors?

Some of these questions were handled very easily. MS with personal experience of the condition. • Other YPwMS were sure they definitely wanted to However, we are not doctors or professors. We cannot give exact information on some points; we can only clarify certain aspects by using our experience. A psychologist in the group shared discussion. The following points were discussed: her experience and advice regarding some points raised in the discussion.



The three mothers in our panel all shared their else that we need to consider. experiences. It was a big advantage to have these mothers among us, because a lot of us are There was a discussion about being selfish or to have children.

symptoms. During their pregnancy, they felt similar Everyone agreed. But then the discussion started MS. They recovered skin sensitivity, the tingling pregnant?" in their hands/feet/limbs had gone, fatigue levels improved as well as many other positive effects. Some thought PwMS should stop their treatment positive influence on the woman's MS.

The group agreed that it is necessary to stop the when the child is born?" treatment(s) during pregnancy. But, anecdotally, there was a known person with MS, who did not Someone came up with a brilliant idea for couples that it is "advised" to stop treatment. Something opportunity for their relationship.

still struggling with the dilemma of whether or not being guilty when choosing whether or not to have children. Someone in the group immediately shared her opinion, "When you try to get pregnant, They were clear: they did not face any new it is not selfish at all to continue your treatment". to how they were before they were diagnosed with again on "What if you don't know yet if you're

They all were in good condition. According to the a few months before they get pregnant due to testimonies, pregnancy can have a significantly the potential side-effects on the foetus. Following this, another point of discussion started: "What/ who can we count on during pregnancy and

know she was pregnant until she gave birth to a to plan quality time together. Asking relatives healthy son! The baby boy was examined but there or friends to take care of the children during a was no problem at all. Was this an exception? weekend, so the person with MS can have some We suppose so. We still shared the same opinion rest and the couple can have uninterrupted

The experience of parenting is wonderful, a big responsibility and every decision involves risk. Not knowing what will happen in the future is a risk for all, not only for persons with MS!



The partners of YPwMS

A lot more needs to be done and organised for partners who face MS every day, deal with the symptoms, the difficulties and the issues! and bigger ones) to let them discuss. We can do it on a face-to-face base, but it can also via alternative meetings or other ways. something about the doubts of the people with no children: most of them were sure to have children before the discussion. But another few still face their dilemma...

at the start of these workshops. It showed a few hormones. They seem to have a positive effect on situations during and after pregnancy and gave pregnant women with MS. some reasonable solutions - ways of helping, supporting the partner of the pregnant PwMS; We all agreed that the video on Sexuality, the parents and close relatives; close friends. Pregnancy and MS will be a "must have" in every There are some services which you can count on MS environment! Social workers, social nurses, after giving birth which offer help with the child the MS communities, the neurologists, everyone and help you to manage your housekeeping.

We do not know exactly where this research conferences and workshops. stands. What about the effects of treatment on the pregnancy? We all agreed that it must not be good. But a lot more research on this needs to be done. What about these children when they grow up? Will they get sick? Does it influence their health? So far, we did not hear a negative story on this issue. But we agreed that research certainly must be continued!

We also referred to the realistic short film, shown We also agreed about the focus on the use of

in the field MUST see this film and they must spread it via websites, Facebook, meetings,

The Italian Experience

Women's project

specific project focused on the implications and the individual but also people who are around aspects that are typical for women, and paying him or her, in all aspects of everyday life, from special attention to what it is like to be a woman the emotional to the practical. The family has long with MS. The aim is to provide accurate tools for been the focus of projects run by the MS Society, women with MS and create with them a direct which aims to provide valuable support for channel for understanding and monitoring their people with MS and their families. By comparing needs. The project proposes various innovative the experiences of those who live every day with ways to focus on all topics of interest to women MS it was possible to collect and identify the main with MS, and involving women, who may then difficulties that families can encounter, with many take on active roles.

Launched in 2007, the project anticipates the creation of an archive of videos online on topics organise annualy: chosen directly by women with MS and the • A4 day stay at the Holiday House in the Sunflowers publication of books on topics specific to women. This project will also encourage the sharing of experience - the telling of personal stories that can help understanding what it means for a woman to live with MS.

Couples and family projects

The Italian MS Society (AISM) has thought up a MS is a complex disease that affects not only of the initiatives designed to address their specific needs.

organisation of seminars - for women only on the The project includes several activities; information subject to promote the dissemination of accurate sessions, opportunities for socialising with MS and up to date information, and foster dialogue and the sharing of expertise, training sessions, and debate. These will be reinforced by the and publications. In particular, it is planned to

> Lucignano during which families will have the opportunity to meet with professionals, such as neurologists, social workers, employment law experts, psychologists, and physical therapists to discuss major concerns and issues related to

mm



MS. The formal sessions are accompanied by Web Quiz information activities for relaxation and recreation AISM has a new information tool: a series of Web for adults and children.

- Weekends for couples spent with a psychologist to examine the internal dynamics of the couple living with MS.
- to promote opportunities for sharing, exchange of experiences and information among peers.
- These activities are connected to the continuing need to produce appropriate publications for the family, either downloadable from the website or found in the library.

quizzes on specific disease topics, to increase knowledge, recount the experiences of people with MS, dispel doubts and facilitate comparison. Web guizzes are useful for testing yourself, • Training meetings for organizing self-help groups answering questions on everything about MS, reading in detail, writing reviews and if possible passing the quizzes. If you get the wrong answer, you can read the right answer, with a small explanation, below the questions.

Busy with a quiz...



Conclusion

Multiple sclerosis affects not only the individual but also the partner, the lover, the family, the friends and all those who experience the repercussions of life with MS. Communication is one of the most valuable tools we have to create change. It is by being strong together, nurturing one another and being active participants in our lives that the needs and issues of life can be dealt with.

Using the personal experiences and the strategies developed, the EMSP Youth Congress wants to ensure that the topics of sexuality and pregnancy will be considered as important as other issues.

It is from the discussions of MS and sexuality and pregnancy in an open way that YPwMS will create a resource pack applicable to all European MS societies. The relationships formed during the first EMSP Youth Congress in 2010 continue to flourish and we all look forward to a better future for YPwMS in Europe.



EMSP Supporting Partners

Thank you for the generous support of our work



EMSP: A UNITED MEMBERSHIP that SPANS THE CONTINENT

Full members

Austria – Belarus - Belgium - Bosnia-Herzegovina - Bulgaria - Croatia - The Czech Republic Denmark - Estonia - Finland - France (LFSEP) - Germany - Greece (GMSS) Hungary (MSMT) - Iceland - Ireland - Italy Latvia - Lithuania - Luxembourg – Malta The Netherlands Norway - Poland - Portugal - Romania - Russia - Serbia - Slovakia Slovenia - Spain (AEDEM-COCEMFE) - Sweden - Switzerland - United Kingdom

Associate members

France (UNISEP) - Greece (Hellenic Federation of Persons with MS) Hungary (SMBOE) - Spain (FELEM)

EXECUTIVE COMMITTEE

President: John C. Golding (Norway) Vice-President: Anne Winslow (Ireland) Treasurer: Torben Damsgaard (Denmark) Past President: Dorothea Pitschnau-Michel (Germany)

Board Members

Prof. Pierre Clavelou (France) Pedro Carrascal (Spain) Dr. Beatrika Končan Vračko (Slovenia) Antonella Moretti (Italy) Emma Rogan (Ireland) André Van de Putte (Belgium)

European Multiple Sclerosis Platform (EMSP)

Rue Auguste Lambiotte 144/8 | B-1030 Brussels | BELGIUM | Tel.: +32 (0) 2 304 50 15 | Fax: +32 (0)2 305 80 11 www.emsp.org | mail: emsp@emsp.org





Hot rythms with the RUMBA CATALANA BAND